Research Article

A Nomogram Predicting the Prognosis of Renal Cell Carcinoma Patients with Lung Metastases

Xinyu Sheng,1,2 Xuan Lu,1,2 Jian Wu,1,2 Lu Chen,1,2 and Hongcui Cao1,2,3

1State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Rd, Hangzhou City 310003, China
2National Clinical Research Center for Infectious Diseases, 79 Qingchun Rd, Hangzhou City 310003, China
3Zhejiang Provincial Key Laboratory for Diagnosis and Treatment of Aging and Physic-chemical Injury Diseases, 79 Qingchun Rd, Hangzhou City 310003, China

Correspondence should be addressed to Hongcui Cao; hccao@zju.edu.cn

Received 3 December 2020; Revised 23 February 2021; Accepted 6 March 2021; Published 19 March 2021

Academic Editor: Min Tang

Copyright © 2021 Xinyu Sheng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. The optimal tool for predicting the survival of renal cell carcinoma (RCC) patients with lung metastases remains controversial. Methods. We selected patients diagnosed with RCC and lung metastases, from 2010 to 2015, from the Surveillance, Epidemiology, and End Results (SEER) database. After the selection of inclusion criteria and exclusion criterion, the rest of the patients were incorporated into model analysis. Least absolute shrinkage and selection operator (LASSO) regression was used to select the most important features for construction of a nomogram predicting cancer-specific survival. A calibration plot and the concordance index (C-index) were used to estimate nomogram efficacy in a validation cohort. The association between important factors selected by LASSO regression, and prognosis was assessed by the Kaplan-Meier (KM) survival curve. The receiver operating characteristic (ROC) curves were drawn to compare sensitivity and specificity between the nomogram we built and the TNM stage-based model. Results. A total of 1,369 patients met the inclusion criteria, but not the exclusion criteria. The LASSO regression model reduced 15 features to seven potential predictors of survival, including tumor grade, the extent of surgery, N and T status, histological profile, and brain and bone metastasis status. Such features had good discrimination in the KM survival curves. The nomogram showed excellent discriminatory power (C-index, 0.71; 95% confidence interval: 0.70 to 0.72) and good calibration in terms of both 1- and 2-year cancer-specific survival. The nomogram showed great discriminatory power (C-index 0.68) and adequate calibration when applied to the validation cohort. The areas under the curve (AUCs) of nomogram were 0.767 and 0.780, respectively, and the AUCs of TNM stage were 0.617 and 0.618 at 1 and 2 years, respectively. Conclusions. Our nomogram might play a major role in predicting the cancer-specific survival of RCC patients with lung metastases.

1. Introduction

Renal cell carcinoma (RCC), a common malignant tumor, accounts for 3.7% of all new tumor cases; RCC is more common in male than female patients, and there are 116,000 deaths annually according to the World Health Organization. The most common pathological type (85%) of RCC is clear cell carcinoma [1, 2]. It is important to accurately predict the survival of RCC patients; however, few efficient predictive tools are available [3–5], particularly for patients with metastatic RCC [6] (which remains incurable). Traditionally, immunochemotherapy has been used to treat nonmetastatic RCC, but the response rate was rarely more than 15%. The clinical prognosis of metastatic RCC is poor, and more studies are required [7]. Lung metastasis is the most common metastasis in RCC patients, but few studies have explored the survival of these patients. An accurate predictive tool would improve tumor control and patient quality of life.

The Surveillance, Epidemiology, and End Results (SEER) database (supported by the American National Cancer Institute) contains clinical and pathological data on cancer patients from 19 regions of the United States and is highly
representative of the general population. Compared to most previous studies which had small sample sizes, our research relied on the SEER database enhances the credibility of this study.

A nomogram is a readily understood visual tool that transforms a complex regression equation to a simple graph; predictions are thus accessible and of high clinical utility. Nomograms find applications in both medical research and clinical practice [8]. The tumor-node-metastasis (TNM) staging system for RCC has been widely used to predict prognosis, but the clinical utility remains unclear [9–11]. Therefore, we developed a nomogram for predicting the cancer-specific survival (CSS) of RCC patients with lung metastases and compared its ROC curves to that of a TNM staging system-based model. Unlike most previous studies, we used a large patient sample that had been extensively evaluated and documented.

2. Materials and Methods

2.1. Patients. Data were obtained from the SEER database. The SEER database covers almost 28% of the US population and is the largest cancer database in the US. All cases are derived from the SEER Program (http://www.seer.cancer.gov) SEER*Stat database (version 8.3.5, accession number: 12099-Nov2018). Abundant information is available, including patient demographics and cancer characteristics. A total of 89,382 patients (including 12,187 stage M1 patients) were newly diagnosed with RCC from 2010 to 2015. The inclusion criteria were as follows: (1) RCC patients from 2010 to 2015 in the US and (2) combined with lung metastases. Thus, we included 1,369 RCC patients with lung metastases in the analysis (Figure 1). Exclusion criteria were as follows: history of other tumors (benign or malignant), age<18, and rare pathological features and data with incomplete information. The following five pathological types of RCC accounted for more than 90% of all cancers: clear cell, papillary, chromophobe, and sarcomatoid RCCs and collecting duct carcinoma (CDC). We excluded patients with other types of carcinoma.

2.2. Clinicopathological Features. The following data were collected: years at diagnosis and evaluation, age, race, sex, extent of surgery (none, partial nephrectomy (PN), or radical nephrectomy (RN)), tumor histology, histological grade, nodal (N) stage, insurance and marital status, laterality, tumor size, CSS, and follow-up duration. There were four histological grades (I–IV). Marital status was classified as “unmarried” (including “single (never married)” and “unmarried”), “married” (including “married under common law”), and “no longer married” (“widowed”, “separated”, and “divorced”). The median survival time was 10 months, and the maximum survival time was 70 months.

2.3. Survival Analysis and Statistical Methods. The primary outcome was the survival time (from hospital admission to the date of death or last follow-up). Clinicopathological features are summarized as median values with interquartile range (IQR), or as frequencies with percentages, for both the training and validation cohorts. The associations of the factors selected from the least absolute shrinkage and selection operator (LASSO) regression analysis with CSS were evaluated by drawing Kaplan-Meier curves. A nomogram
Table 1: Clinicopathological characteristics of RCC patients with lung metastases.

| Characteristic          | Primary cohort (n = 976) | Validation cohort (n = 393) | \( P \) value |
|-------------------------|-------------------------|----------------------------|---------------|
|                         | No. of patients | %           | No. of patients | %           |
| Age (years)             | 60                  | 60          |               |   | 0.72 |
| Median                  | Range               | Range       |               |   |           |
| Sex                     | 0.252               |             |               |   |           |
| Male                    | 705                 | 72.2        | 271           | 69 |           |
| Female                  | 271                 | 27.8        | 122           | 31 |           |
| Race                    | 0.937               |             |               |   |           |
| White                   | 831                 | 85.1        | 335           | 85.2 |           |
| Black                   | 64                  | 6.6         | 24            | 6.1 |           |
| Other                   | 81                  | 8.3         | 34            | 8.7 |           |
| Grade                   | 0.928               |             |               |   |           |
| I                       | 29                  | 3           | 10            | 2.5 |           |
| II                      | 188                 | 19.3        | 77            | 19.6 |           |
| III                     | 405                 | 41.5        | 158           | 40.2 |           |
| IV                      | 354                 | 36.3        | 148           | 37.7 |           |
| Laterality              | 1                   |             |               |   |           |
| Left                    | 480                 | 49.2        | 193           | 49.1 |           |
| Right                   | 496                 | 50.8        | 200           | 50.9 |           |
| T                       | 0.859               |             |               |   |           |
| T1a                     | 19                  | 1.9         | 6             | 1.5 |           |
| T1b                     | 82                  | 8.4         | 29            | 7.4 |           |
| T2a                     | 89                  | 9.1         | 43            | 10.9 |           |
| T2b                     | 83                  | 8.5         | 36            | 9.2 |           |
| T3                      | 572                 | 58.6        | 224           | 57  |           |
| T4                      | 131                 | 13.4        | 55            | 14  |           |
| N                       | 0.875               |             |               |   |           |
| N1                      | 304                 | 31.1        | 120           | 30.5 |           |
| N0                      | 672                 | 68.9        | 273           | 69.5 |           |
| Surgery                 | 0.659               |             |               |   |           |
| No surgery              | 231                 | 23.7        | 84            | 21.4 |           |
| PN                      | 19                  | 1.9         | 8             | 2  |           |
| RN                      | 726                 | 74.4        | 301           | 76.6 |           |
| Tumor size (mm)         | 0.356               |             |               |   |           |
| Median                  | 95                  | 100         |               |   |           |
| Range                   | 75-120              | 75-120      |               |   |           |
| Pathological type       | 0.582               |             |               |   |           |
| pRCC                    | 28                  | 2.9         | 12            | 3.1 |           |
| ccRCC                   | 697                 | 71.4        | 288           | 73.3 |           |
| RCC, NOS                | 168                 | 17.2        | 53            | 13.5 |           |
| sRCC                    | 8                   | 0.8         | 3             | 0.8 |           |
| chRCC                   | 63                  | 6.5         | 30            | 7.6 |           |
| CDC                     | 12                  | 1.2         | 7             | 1.8 |           |
| Brain metastasis        | 0.421               |             |               |   |           |
| Yes                     | 116                 | 11.9        | 40            | 10.2 |           |
| No                      | 860                 | 88.1        | 353           | 89.8 |           |
| Bone metastasis         | <0.001              |             |               |   |           |
| Yes                     | 116                 | 11.9        | 78            | 19.8 |           |
| No                      | 860                 | 88.1        | 315           | 80.2 |           |
was created based on the results of the LASSO regression. Discriminatory power was quantified using the concordance index (C-index). The “rms” R package was used to evaluate the nomogram and draw calibration curves. All statistical analyses were performed using R software (ver. 3.5.3; R Foundation for Statistical Computing, Vienna, Austria). All tests were two-sided and a P value < 0.05 was considered statistical significance.

### 3. Results

#### 3.1. Clinicopathological Characteristics

Of the 6,685 RCC patients who developed lung metastases from 2010 to 2015, 1,369 were included in the final analysis (976 in the training cohort and 393 in the validation cohort; Table 1). We considered the three major types of metastases (the brain, bone, and liver). The gross pathological types were clear cell, papillary, chromophobe, and sarcomatoid RCCs and CDC. The median age of both cohorts was 60 years, where RCC is more common in the elder. The median follow-up time was 10 months (range: 1–70 months) and the 1- and 2-year CSS rates were 53.9 and 34.8%, respectively.

#### 3.2. Feature Selection and Prognostic Signature Building

We reduced the initial 15 features of the 976 patients in the training cohort to seven potential predictors of survival: T status (coefficient, 0.106) N status (coefficient, 0.440), tumor grade (coefficient, 0.211), extent of surgery (coefficient, -0.490), pathology (coefficient, 0.120), and brain and bone metastasis status (coefficient, 0.581 and 0.464) (Figure 2). Feature selection was performed using a LASSO binary logistic regression model. Dotted vertical lines were drawn at the optimal values (derived using the minimal criteria with one standard error (the “1-SE” criteria), see Figure 1). The final λ value was

---

**Table 1: Continued.**

| Characteristic       | Primary cohort (n = 976) | Validation cohort (n = 393) | P value |
|----------------------|--------------------------|----------------------------|---------|
| Liver metastasis     |                          |                            |         |
| Yes                  | 131                      | 47                         | 0.523   |
| No                   | 845                      | 346                        |         |
| Insurance status     |                          |                            | 0.93    |
| Yes                  | 936                      | 378                        |         |
| No                   | 40                       | 15                         |         |
| Marital status       |                          |                            | 0.115   |
| Unmarried            | 155                      | 57                         |         |
| Married              | 642                      | 280                        |         |
| Negative married     | 179                      | 56                         |         |

Abbreviations: ccRCC: clear cell renal cell carcinoma; pRCC: papillary renal cell carcinoma; chRCC: chromophobe renal cell carcinoma; sRCC: sarcomatoid renal cell carcinoma; CDC: collecting duct carcinoma.

---

**Figure 2:** Feature selection using a least absolute shrinkage and selection operator (LASSO) regression model. (a) Tuning parameter (λ) selection for the LASSO model involved fivefold cross-validation using the minimal criteria. Dotted vertical lines were drawn at the optimal values; one standard error was added to each criterion to yield the 1-SE criteria. (b) The LASSO coefficients of the 15 features.
Figure 3: Continued.
0.068 and the log (λ) value was -2.687. We included the coefficient profiles of all 15 features in the diagram.

3.3. Kaplan-Meier Curves of Significant Features. All seven potential predictors of survival were found to be useful for predicting CSS in the training cohort (Figure 3). It was clear that patients lacking metastases had better CSS, which was also significantly enhanced by PN or RN. Patients receiving operation (either PN or RN) had a better CSS than those who did not. Not surprisingly, lymph node metastasis could not afford a significant survival benefit. The significant differences in tumor grade and histology among RCC types also affected the CSS outcomes.

3.4. A Prognostic Nomogram for CSS. The prognostic nomogram comprising all factors that significantly affected CSS is shown in Figure 4. The C-index for CSS prediction was 0.71 (95% confidence interval: 0.70 to 0.72). The calibration plots for the 1- and 2-year survival probabilities of RCC patients with lung metastases revealed excellent agreement between prediction and observation in training cohort (Figures 5(a) and 5(b)).
3.5. Validation of Predictive Accuracy. The follow-up time in the validation cohort was 10 months (range: 1–67 months) and the 1- and 2-year CSS rates were 56.3 and 43.1%, respectively. The C-index of the nomogram for CSS prediction was 0.68. The calibration plots of the survival probability of the validation cohort, for 1 and 2 years after RCC diagnosis, revealed good agreement between prediction and observation.

3.6. ROC Comparison with TNM Stage. We then applied the time-dependent ROC curves to compare sensitivity and specificity between the nomogram we built and the TNM stage at 1 and 2 years. The areas under the curve (AUCs) of the nomogram were 0.767 and 0.780, respectively, and the AUCs of TNM stage were 0.617 and 0.618 at 1 and 2 years, respectively (Figure 6).

4. Discussion

In a LASSO regression, seven prognostic factors for RCC patients with lung metastases were identified, based on which a nomogram was constructed including tumor grade, extent of surgery, pathology, brain metastasis status, and bone metastasis status. This was used to predict 1- and 2-year CSS in a large cohort of metastatic RCC patients drawn from the SEER database. The nomogram was validated, internally and externally, in terms of its discriminatory power and calibration.

There exist several outcome prediction models for RCC patients, though none of them is developed for patients with lung metastases. Due to the natural differences in tumor microenvironment, models set for metastatic and nonmetastatic RCC are different. The stage, size, grade, and necrosis
(SSIGN) score and the University of California Los Angeles Integrated Staging System (UISS) are two widely used tools for prognosis prediction [12, 13]. SSIGN score is calculated to divide localized RCC patients into three groups and to predict 5-year metastasis-free survival rate. UISS can be used to predict 5-year disease-specific survival for both metastatic and nonmetastatic RCC patients, which includes T stage, Fuhrman’s grade, and ECOG (Eastern Cooperative Oncology Group) status. Besides the two common tools for prediction, other three prognostic models are performed in the previous studies [14–16].

As for metastatic RCC, prediction tools are used for either selecting those patients who might benefit from adjuvant treatment or predicting survival rate. The patients care more about their survival time. Previous studies have launched some prediction models based on demographic and tumor pathology information [17, 18]. However, most of them just proposed prognostic factors, rather than integrating them into scores and presenting them in a concise form.

The effect of lung metastases on prognosis in RCC patients remained controversial. A research with 782 patients from Groupe Français d’Immunothérapie took diverse
metastatic sites including the lung, mediastinum, bone, and liver into consideration, and the results showed that only the lung metastasis was not associated with overall survival [19]. Similarly, a retrospective study showed that the overall survival did not differ between patients with less than 8.5 months and more than 8.5 months [20]. However, as lung metastasis is the most common metastasis in RCC patients, it is hard to say that it has no effect on the overall survival of RCC. This can be corroborated by a study on adult metastatic RCC that lung metastasis together with weight loss and disease-free interval resulted in a worse survival [21]. Also, although there were several prognostic tools for RCC patients with lung metastasis, none of them was developed for RCC patients with lung metastases, which is exactly what we want to do in this study.

Currently, only few dedicated models predict the overall survival (OS) or CSS of RCC patients, particularly those with metastases. A model based on the TNM staging system is currently the default clinical model, and it evaluates tumor size and local extension of the primary tumor (T), regional lymph node involvement (N), and distant metastasis status (M) [22, 23]. Because we evaluated metastatic RCC patients, T and N status were retained in our nomogram. Although the TNM-based model is widely used to predict the survival of RCC patients, it is unclear whether the model is appropriate. A few studies found that models based on the TNM staging system were inaccurate in terms of predicting the RCC survival rate [24]. One study even reported no association between TNM staging system data and RCC patient outcomes. A study of more than 500 nonmetastatic RCC patients found that the prognostic utility of the TNM staging system was limited [25]. Few studies have focused on metastatic RCC; it is essential to establish a novel tool for predicting the outcomes (especially survival rates) of metastatic RCC patients. Most RCC metastases are in the lungs; these patients require special attention. The TNM staging system is clearly biased, emphasizing pathological indicators over other, such as clinical and treatment characteristics, which are more important from our perspectives.

We searched all the metastatic RCC prognostic models and compiled them into Table S1 in the Supplementary Material. Among these models, “performance status,” “signs of inflammation,” and some biochemical indicators including ALP, calcium, LDH, hemoglobin, and WBC count were not included in the SEER database, which is one limitation of analysis. However, although these models were developed for a while, none of them was compared with the traditional TNM staging system, which is worth to be taken into consideration. The nomogram we developed exhibited great discriminatory power and the CSS of the training and validation cohorts were well-calibrated. It proved that this prognostic model is stable and convincing. Also, we concerned the two types of surgical methods, PN and RN, since they might affect the patients’ perioperative state and therefore affect the survival of RCC patients with lung metastases.

A nomogram is an intuitive visual tool for predicting disease survival and can be used to explain survival probability to patients in a straightforward manner. Many authors now use nomograms to predict disease (including RCC) survival rates [26, 27]. Nomograms containing more information than the TNM staging system; they better predict the outcomes of patients with pancreatic and hepatic carcinoma [28, 29] and RCC. We considered seven factors including pathological type and clinical and treatment characteristics, to minimize bias when predicting prognosis.

The strengths of our study were as follows. First, our nomogram is the only tools effective for predicting the CSS of RCC patients with lung metastases among existing models. Indeed, it is an effective bridge connecting doctors and patients. Second, we focused on a specialized cohort, i.e., RCC patients with lung metastases (the most common
metastasis in these patients). Third, our study is a good representative of the general population. The SEER database we used covers the entire United States and is thus much larger and more comprehensive than single-center databases; this feature enhances the credibility of our study.

This study also had some limitations. First, our research lacks external validation, though the SEER database compensates for the homogeneity of patients from single research center to some extent as it covers millions of patients all around US. Second, as the study was retrospective in nature, patient allocation to the training and validation cohorts may have been biased; randomized control trials are needed. Third, some biochemical indicators including ALP, calcium, LDH, hemoglobin, and WBC count were not included in the SEER database and the discriminatory power of our nomogram could not be compared with other prognostic models. Also, a larger cohort would have allowed us to detect small differences between patient subgroups. Finally, unknown factors may affect the CSS of RCC patients with lung metastases. More data are needed to confirm the effectiveness of the nomogram; to this end, a prospective study is planned.

5. Conclusion
The novel prognostic model based on the SEER database could predict the cancer-specific survival of RCC patients with lung metastases.

Data Availability
The data used to support the findings of this study are included within the article.

Conflicts of Interest
No author has any conflict of interest in terms of the subject matter or the materials discussed in this paper.

Acknowledgments
We thank the SEER database owners for giving us the opportunity to analyze some of their data.

Supplementary Materials
Supplementary Table S1: characteristics in various prognostic models for metastatic RCC. (Supplementary Materials)

References
[1] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2017,” CA: a Cancer Journal for Clinicians, vol. 67, no. 1, pp. 7–30, 2017.
[2] U. Capitanio, K. Bensalah, A. Bex et al., “Epidemiology of renal cell carcinoma,” European Urology, vol. 75, no. 1, pp. 74–84, 2019.
[3] G. Zhang, Y. Wu, J. Zhang et al., “Nomograms for predicting long-term overall survival and disease-specific survival of patients with clear cell renal cell carcinoma,” Oncotargets and Therapy, vol. Volume 11, pp. 5535–5544, 2018.
[4] S. Buti, P. I. Karakiewicz, M. Bersanelli et al., “Validation of the GaRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: a new tool to predict survival in surgically treated renal cell carcinoma patients,” Scientific Reports, vol. 9, no. 1, p. 13218, 2019.
[5] W. Zhou, C. Huang, and N. Yuan, “Prognostic nomograms based on log odds of positive lymph nodes for patients with renal cell carcinoma: a retrospective cohort study,” International journal of surgery (London, England), vol. 60, pp. 28–40, 2018.
[6] W. J. Xiao, Y. Zhu, B. Dai, H. L. Zhang, and D. W. Ye, “Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: a seer analysis,” International braz j urol : official journal of the Brazilian Society of Urology, vol. 41, no. 2, pp. 288–295, 2015.
[7] G. Rosiello, S. Knipper, C. Palumbo et al., “Unmarried status is a barrier for access to treatment in patients with metastatic renal cell carcinoma,” International Urology and Nephrology, vol. 51, no. 12, pp. 2181–2188, 2019.
[8] A. Iasonos, D. Schrag, G. V. Raj, and K. S. Panageas, “How to build and interpret a nomogram for cancer prognosis,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol. 26, no. 8, pp. 1364–1370, 2008.
[9] M. Sun, S. F. Shariat, C. Cheng et al., “Prognostic factors and predictive models in renal cell carcinoma: a contemporary review,” European Urology, vol. 60, no. 4, pp. 644–661, 2011.
[10] B. Ljungberg, K. Bensalah, S. Canfield et al., “EUA guidelines on renal cell carcinoma: 2014 update,” European Urology, vol. 67, no. 5, pp. 913–924, 2015.
[11] V. Ficarra, G. Novara, A. Galfano, and W. Artibani, “Neoplasm staging and organ-confined renal cell carcinoma: a systematic review,” European Urology, vol. 46, no. 5, pp. 559–564, 2004.
[12] B. C. Leibovich, M. L. Blute, J. C. Cheville et al., “Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials,” Cancer, vol. 97, no. 7, pp. 1663–1671, 2003.
[13] A. Zisman, A. J. Pantuck, F. Dorey et al., “Improved prognostication of renal cell carcinoma using an integrated staging system,” Journal of Clinical Oncology, vol. 19, no. 6, pp. 1649–1657, 2001.
[14] P. I. Karakiewicz, A. Briganti, F. K.-H. Chun et al., “Multinstitutional validation of a new renal cancer–specific survival nomogram,” Journal of Clinical Oncology, vol. 25, no. 11, pp. 1316–1322, 2007.
[15] M. I. C. H. A. E. L. KATTAN, V. I. C. T. O. R. REUTER, R. O. B. E. R. T. J. MOTZER, J. A. R. E. D. KATZ, and P. A. U. L. RUSSO, “A postoperative prognostic nomogram for renal cell carcinoma,” The Journal of Urology, vol. 166, no. 1, pp. 63–67, 2001.
[16] M. A. X. I. M. I. A. N. O. SORBELLINI, M. I. C. H. A. E. L. W. KATTAN, M. A. R. K. E. SNYDER et al., “A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma,” The Journal of Urology, vol. 173, no. 1, pp. 48–51, 2005.
[17] R. J. Motzer, M. Mazumdar, J. Bacik, W. Berg, A. Amsterdam, and J. Ferrara, “Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma,” Journal of Clinical Oncology, vol. 17, no. 8, pp. 2530–2540, 1999.
[18] R. J. Motzer, J. Bacik, L. H. Schwartz et al., "Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma," *Journal of Clinical Oncology*, vol. 22, no. 3, pp. 454–463, 2004.

[19] S. Négrier, B. Escudier, F. Gomez et al., "Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d’Immunotherapie," *Annals of Oncology*, vol. 13, no. 9, pp. 1460–1468, 2002.

[20] S. H. Culp, N. M. Tannir, E. J. Abel et al., "Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?" *Cancer*, vol. 116, no. 14, pp. 3378–3388, 2010.

[21] A. de Forges, A. Rey, M. Klink, M. Ghosn, A. Kramar, and J. P. Droz, "Prognostic factors of adult metastatic renal carcinoma: a multivariate analysis," *Seminars in Surgical Oncology*, vol. 4, no. 3, pp. 149–154, 1988.

[22] V. Ficarra, A. Galfano, M. Mancini, G. Martignoni, and W. Artibani, "TNM staging system for renal-cell carcinoma: current status and future perspectives," *The Lancet. Oncology*, vol. 8, no. 6, pp. 554–558, 2007.

[23] M. K. Gospodarowicz, D. Miller, P. A. Groome et al., "The process for continuous improvement of the TNM classification," *Cancer*, vol. 100, no. 1, pp. 1–5, 2004.

[24] C. Terrone, C. Cracco, F. Porpiglia et al., "Reassessing the current TNM lymph node staging for renal cell carcinoma," *European Urology*, vol. 49, no. 2, pp. 324–331, 2006.

[25] C. Terrone, P. Gontero, A. Volpe et al., "Proposal of an improved prognostic classification for pT3 renal cell carcinoma," *The Journal of Urology*, vol. 180, no. 1, pp. 72–78, 2008.

[26] V. P. Balachandran, M. Gonen, J. I. Smith, and R. P. DeMatteo, "Nomograms in oncology: more than meets the eye," *The Lancet. Oncology*, vol. 16, no. 4, pp. e173–e180, 2015.

[27] I. G. O. R. FRANK, M. I. C. H. A. E. L. BLUTE, J. O. H. N. C. CHEVILLE, C. H. R. I. S. T. I. N. E. M. LOHSE, A. M. Y. L. WEAVER, and H. O. R. S. T. ZINCKE, "An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score," *The Journal of Urology*, vol. 168, no. 6, pp. 2395–2400, 2002.

[28] N. Pu, J. Li, Y. Xu et al., "Comparison of prognostic prediction between nomogram based on lymph node ratio and AJCC 8th staging system for patients with resected pancreatic head carcinoma: a SEER analysis," *Cancer management and research 10*, vol. Volume 10, pp. 227–238, 2018.

[29] C. Y. Jing, Y. P. Fu, H. J. Shen et al., "Albumin to gamma-glutamyltransferase ratio as a prognostic indicator in intrahepatic cholangiocarcinoma after curative resection," *Oncotarget*, vol. 8, no. 8, pp. 13293–13303, 2017.